当前位置: X-MOL首页最新SCI期刊查询及投稿分析系统 › American Journal of Cardiovascular Drugs杂志
American Journal of Cardiovascular Drugs
基本信息
期刊名称 American Journal of Cardiovascular Drugs
AM J CARDIOVASC DRUG
期刊ISSN 1175-3277
期刊官方网站 http://link.springer.com/journal/40256
是否OA
出版商 Adis International Ltd
出版周期 Bimonthly
始发年份 2001
年文章数 48
最新影响因子 3.0(2022)  scijournal影响因子  greensci影响因子
中科院SCI期刊分区
大类学科 小类学科 Top 综述
医学3区 CARDIAC & CARDIOVASCULAR SYSTEMS 心脏和心血管系统4区
PHARMACOLOGY & PHARMACY 药学3区
CiteScore
CiteScore排名 CiteScore SJR SNIP
学科 排名 百分位 2.12 0.903 0.819
Medicine
Cardiology and Cardiovascular Medicine
89 / 322 72%
Medicine
Pharmacology (medical)
92 / 232 60%
补充信息
自引率 3.30%
H-index 42
SCI收录状况 Science Citation Index Expanded
官方审稿时间
Submission to first decision
36 days
网友分享审稿时间 数据统计中,敬请期待。
PubMed Central (PML) http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1175-3277%5BISSN%5D
投稿指南
期刊投稿网址 https://www.editorialmanager.com/cvda/default.aspx
收稿范围

The American Journal of Cardiovascular Drugs promotes rational therapy and effective patient management within the discipline of cardiology by providing a regular program of independent review articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established agents and procedures. The journal includes:

  • Short overviews of contentious or emerging issues (Current Opinions and Leading Articles, respectively).
  • Comprehensive narrative reviews on therapeutic approaches to managing cardiovascular disease.
  • Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
  • Therapy in practice reviews covering optimum management of specific conditions.
  • Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in cardiovascular medicine.
  • Original research articles reporting the results of well-designed clinical studies, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic studies.

Additional enhanced features (including slide sets, videos and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in the American Journal of Cardiovascular Drugs may be accompanied by plain language summaries to assist readers in understanding important medical advances.

All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.


收录体裁
投稿指南
投稿模板
参考文献格式
编辑信息

Editor (Adis International Limited, Auckland, New Zealand):

Amitabh Prakash

Consulting Editor:

A. Michael Lincoff, Cleveland Clinic Foundation, Cleveland, OH, USA

Editorial Board:

A. Barseghian El-Farra, University of California at Irvine, Irvine, CA, USA

B. Bhargava, All India Institute of Medical Sciences, New Delhi, India

D.L. Bhatt, Brigham and Women’s Hospital Heart & Vascular Center, Boston, MA, USA

P.C. Deedwania, University of California at San Francisco, Fresno, CA, USA

N.S. Dhalla, Institute of Cardiovascular Sciences, Winnipeg, MB, Canada 

P. Erwin, South Miami Heart Specialists, South Miami, FL, USA

A.M. Feldman, Temple University School of Medicine and Temple University Health System, Philadelphia, PA, USA

V. Fuster, Mount Sinai Medical Center, New York, NY, USA

X. Girerd, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

S. Goldstein, Henry Ford Heart and Vascular Institute, Detroit, MI, USA

J.A. Hill, UT Southwestern Medical Center, Dallas, TX, USA

G. Jagadeesh, Silver Spring, MD, USA

N.S. Kleiman, The Methodist DeBakey Heart Center , Houston, TX, USA

A. Lafont, Université Paris-Descartes, Paris, France

T.H. Le Jemtel, Tulane University Medical School, New Orleans, LA, USA

M. Marzilli, University of Pisa, Pisa, Italy

V. Menon, Cleveland Clinic, Cleveland, OH, USA

G. Montalescot, Pitié-Salpêtrière University Hospital, Paris, France

D. Morrone, University of Pisa, Pisa, Italy

S. Nicholls, Monash University, Melbourne, VIC, Australia

A. Oto, Hacettepe University School of Medicine, Ankara, Turkey

B. Pitt, University of Michigan Hospital, Ann Arbor, MI, USA

S. G. Priori, Fondazione Salvatore Maugeri, Pavia, Italy

C.V.S. Ram, Texas Blood Pressure Institute, Dallas, TX, USA

G. Reboldi, University of Perugia, Perugia, Italy

G. Santulli, Albert Einstein College of Medicine, New York, NY, USA

J. Silvain, Institut de Cardiologie, Paris, France

K.K. Talwar, Max Super Speciality Hospital, New Delhi, India

M. Tendera, Medical University of Silesia, Katowice, Poland

U. Thadani, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

A. Vahanian, Groupe Hospitalier Bichat-Claude Bernard, Paris, France

G.W. Vetrovec, Virginia Commonwealth University, Richmond, VA, USA

M.A. Weber, State University of New York, New York, NY, USA

W.S. Weintraub, MedStar Heart and Vascular Institute, Washington, DC, USA

H.D. White, Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand

B.S. Wiggins, Medical University of South Carolina, Charleston, SC, USA

N.D. Wong, University of California at Irvine, Irvine, CA, USA


我要分享  (欢迎您来完善期刊的资料,分享您的实际投稿经验)
研究领域:
投稿录用情况: 审稿时间:  个月返回审稿结果
本次投稿点评:
提交
down
wechat
bug